211 related articles for article (PubMed ID: 23585663)
1. A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults.
Yuen KC; Conway GS; Popovic V; Merriam GR; Bailey T; Hamrahian AH; Biller BM; Kipnes M; Moore JA; Humphriss E; Bright GM; Cleland JL
J Clin Endocrinol Metab; 2013 Jun; 98(6):2595-603. PubMed ID: 23585663
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.
Moore WV; Nguyen HJ; Kletter GB; Miller BS; Rogers D; Ng D; Moore JA; Humphriss E; Cleland JL; Bright GM
J Clin Endocrinol Metab; 2016 Mar; 101(3):1091-7. PubMed ID: 26672637
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
4. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile.
Rasmussen MH; Bysted BV; Anderson TW; Klitgaard T; Madsen J
J Clin Endocrinol Metab; 2010 Jul; 95(7):3411-7. PubMed ID: 20427496
[TBL] [Abstract][Full Text] [Related]
5. Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile.
Rasmussen MH; Jensen L; Anderson TW; Klitgaard T; Madsen J
Clin Endocrinol (Oxf); 2010 Dec; 73(6):769-76. PubMed ID: 20718773
[TBL] [Abstract][Full Text] [Related]
6. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency.
Søndergaard E; Klose M; Hansen M; Hansen BS; Andersen M; Feldt-Rasmussen U; Laursen T; Rasmussen MH; Christiansen JS
J Clin Endocrinol Metab; 2011 Mar; 96(3):681-8. PubMed ID: 21177789
[TBL] [Abstract][Full Text] [Related]
7. Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency.
Rasmussen MH; Janukonyté J; Klose M; Marina D; Tanvig M; Nielsen LF; Höybye C; Andersen M; Feldt-Rasmussen U; Christiansen JS
J Clin Endocrinol Metab; 2016 Mar; 101(3):988-98. PubMed ID: 26727076
[TBL] [Abstract][Full Text] [Related]
8. Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults.
Ku CR; Brue T; Schilbach K; Ignatenko S; Magony S; Chung YS; Kim BJ; Hur KY; Kang HC; Kim JH; Kim MS; Kowalska A; Bolanowski M; Ruchala M; Damjanovic S; Payer J; Choi YJ; Heo SJ; Kim TK; Heo M; Lee J; Lee EJ
Eur J Endocrinol; 2018 Sep; 179(3):169-179. PubMed ID: 29973375
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.
Hou L; Chen ZH; Liu D; Cheng YG; Luo XP
Drug Des Devel Ther; 2016; 10():13-21. PubMed ID: 26719670
[TBL] [Abstract][Full Text] [Related]
10. A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life.
Cleland JL; Geething NC; Moore JA; Rogers BC; Spink BJ; Wang CW; Alters SE; Stemmer WP; Schellenberger V
J Pharm Sci; 2012 Aug; 101(8):2744-54. PubMed ID: 22678811
[TBL] [Abstract][Full Text] [Related]
11. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile.
Rasmussen MH; Olsen MW; Alifrangis L; Klim S; Suntum M
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1819-29. PubMed ID: 25013997
[TBL] [Abstract][Full Text] [Related]
12. Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children.
Zelinska N; Iotova V; Skorodok J; Malievsky O; Peterkova V; Samsonova L; Rosenfeld RG; Zadik Z; Jaron-Mendelson M; Koren R; Amitzi L; Raduk D; Hershkovitz O; Hart G
J Clin Endocrinol Metab; 2017 May; 102(5):1578-1587. PubMed ID: 28323965
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
[TBL] [Abstract][Full Text] [Related]
14. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Teichman SL; Neale A; Lawrence B; Gagnon C; Castaigne JP; Frohman LA
J Clin Endocrinol Metab; 2006 Mar; 91(3):799-805. PubMed ID: 16352683
[TBL] [Abstract][Full Text] [Related]
15. An individualized GH dose regimen for long-term GH treatment in Japanese patients with adult GH deficiency.
Chihara K; Koledova E; Shimatsu A; Kato Y; Kohno H; Tanaka T; Teramoto A; Bates PC; Attanasio AF
Eur J Endocrinol; 2005 Jul; 153(1):57-65. PubMed ID: 15994746
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency.
Liang Y; Zhang C; Wei H; Du H; Zhang G; Yang Y; Zhang H; Gong H; Li P; Song F; Xu Z; He R; Zhou W; Zheng H; Sun L; Luo X
Front Endocrinol (Lausanne); 2022; 13():922304. PubMed ID: 36034448
[TBL] [Abstract][Full Text] [Related]
17. A long-acting pegylated recombinant human growth hormone (Jintrolong
Guan Y; He F; Wu J; Zhao L; Wang X; Huang L; Zeng G; Ren B; Chen J; Liao X; Ma Z; Chen X; Zhong G; Huang M; Zhao X
J Clin Pharm Ther; 2018 Oct; 43(5):640-646. PubMed ID: 29959799
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of once-weekly administration of JR-142, a long-acting albumin-fused human growth hormone: A rondemized, placebo-controlled phase 1 study.
Owada Y; Okazaki M; Ikeda T; Yamamoto R; Minami K; Takahashi K; Hirato T; Mita Y; Yamamoto T; Tanizawa K; Sonoda H; Sato Y
Growth Horm IGF Res; 2022 Dec; 67():101500. PubMed ID: 36113378
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the peripheral sensitivity to growth hormone in adults with GH deficiency.
Aimaretti G; Fanciulli G; Bellone S; Maccario M; Arvat E; Delitala G; Camanni F; Ghigo E
Eur J Endocrinol; 2001 Sep; 145(3):267-72. PubMed ID: 11517006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
